The Drug Eluting Technology Show

The Drug Eluting Technology Show is a full educational program featuring a panel of experts, Key opinion leaders, aiming at raising awareness about the use of drug-eluting technologies, which have emerged as effective and safe options for treating PAD, especially when compared to POBA or bare metal stents.

• This program aim at collecting clinical cases featuring any DET medical device used in treating patients with PAD to help grow the knowledge in the scientific community.
• Enhance your skills by joining the live case procedure planned to be streamed live from a center located in the United kingdoms with a stellar panel of experts commenting the case. Learn more about how to deal with complex lesions as well as how to effectively manage long lesions vs other lesions.
• Get the latest updates and guidelines from the clinical community about the benefits of Drug Eluting Technology in treating PAD and what the future holds.

Don’t miss this opportunity. This program is CME accredited.

Register now if you are not an Incathlab member yet

Program Agenda :

Part 1
The Drug Eluting Technology : Where we stand now?

1. Paclitaxel Safety

• Overview of recent findings on the safety profile of paclitaxel.
• Discussion of the FDA's updated stance on paclitaxel-coated devices.
• Recent guidelines – for example ESC – New reviews “State of the Art” publication (Yann) and True PTX.
• Examination of the latest meta-analysis and its implications for clinical practice.

2. DES & DCB Benefits Over BMS and POBA

• Comparison of drug-eluting stents (DES) and with bare-metal stents (BMS).
• Drug-coated balloons (DCB) and plain old balloon angioplasty (POBA).
• Analysis of long-term outcomes, including restenosis rates and reintervention needs.
• Review of clinical studies supporting the efficacy of DES and DCB.

3. By-Pass verse DET and amputation rates on PTX leverage True PTX and DETECT

4. Paclitaxel vs. Limus

• Comparison of paclitaxel-based therapies with limus-based therapies in vascular interventions.
• Discussion on mechanisms of action, efficacy, and safety profiles.
• Review of clinical evidence supporting the use of each drug class.

5. The Restenosis Challenge

• Overview of the mechanisms leading to restenosis after vascular interventions.
• Current strategies to mitigate restenosis, including advancements in medical device technology.
• Case studies highlighting successful management of restenosis.

6. Managing lesion types: DES Vs DCB optimal strategy?

• Strategies for managing patients with vascular conditions: SPORTS data Highlight.
• Dealing with long and complex lesions deserves a good preparation of the vessel for drug uptake.
• Discussion on multidisciplinary approaches and individualized treatment plans.

Part 2
Livecase procedure from UK

Part 3
Sharing experiences and best practices: the DET Clinical Cases collected review and discussion

• Clinical Case #1
• Clinical Case #2
• Clinical Case #3
• Clinical Case #4